The prefilled, patient-ready-to-use system is said to support delivery of high-viscosity biologics of up to 50 centipoise.

Subcutaneous injections do not require a port like an IV, eliminating the risk for port-related complications such as infections.

News PR Newswire Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist ...

What if you could inject a drug into a "problem area" – like abdominal fat – that could kill off fat cells and reduce fat ...

The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase ...

Ocrevus subcutaneous injection was non-inferior to Ocrevus IV infusion as measured by Ocrevus levels in the blood of patients (area under the serum concentration time curve) from day 1 to 12 weeks ...

The Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), a subcutaneous injection, for all previously approved indications of the intravenous ...

Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, ...

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical ...

The subcutaneous route allows drugs such as insulin and heparin to be absorbed slowly over a period of time. Using the correct injection technique and selecting the correct site will minimise the risk ...